The global critical limb ischemia treatment market size was valued at USD 5.39 billion in 2025 and is projected to grow from USD 5.71 billion in 2026 to USD 9.07 billion by 2034, registering a CAGR of 5.95% during the forecast period (2026–2034). North America dominated the critical limb ischemia treatment market with a share of 43.31% in 2025.
Critical limb ischemia (CLI) treatment refers to medical and interventional approaches used to manage severe peripheral artery disease (PAD) associated with chronic ischemic rest pain, non-healing wounds or ulcers, and gangrene. Treatment approaches include endovascular revascularization, surgical bypass, wound care, pain management, and other therapies intended to restore blood flow, promote wound healing, and preserve limb function. Critical limb ischemia treatment products and devices are tracked under HSN Code 9018 (instruments and appliances used in medical or surgical sciences) and SIC Code 3841 (surgical and medical instruments and apparatus).
The critical limb ischemia treatment market demand is supported by the increasing prevalence of peripheral artery disease, the rising incidence of gangrene, and the need for limb-preserving interventions. Healthcare providers are increasingly using endovascular, surgical, and hybrid revascularization approaches to restore blood flow, relieve ischemic pain, heal wounds, and minimize tissue loss, contributing to critical limb ischemia treatment market growth.
• 2025 Market Size: USD 5.39 Billion• 2026 Market Size: USD 5.70 Billion• 2034 Projected Market Size: USD 9.06 Billion• Forecast Period: 2026–2034• Base Year: 2025• Market CAGR (2026–2034): 5.95%
• Largest Regional Market (2025): North America• North America Market Share (2025): 43.31%• Fastest-growing Region: Asia Pacific• Asia Pacific CAGR (2026–2034): 7.27%
By Treatment Type
• Leading Segment: Devices• Market Share in 2025: 54.62%
By End User
• Fastest-growing Segment: Ambulatory Surgical Centers• CAGR: 6.48% (2026–2034)
Download a Free Sample To learn more about this report,
Development of Intravascular Lithotripsy for Calcified Lesions
The critical limb ischemia treatment market analysis shows that intravascular lithotripsy is being used to modify heavily calcified arteries before or during revascularization procedures. The technology uses controlled sonic pressure waves to break calcium within the vessel and improve access for further treatment. This development strengthens treatment options for complex calcified lesions in critical limb ischemia.
Expansion of Ambulatory CLTI Revascularization
Critical limb ischemia revascularization is increasingly being performed in ambulatory surgical centers and outpatient laboratories for selected patients. These settings can support shorter stays and reduce the need for prolonged hospital care after suitable procedures. This shift broadens the use of outpatient pathways in limb salvage treatment.
Supply chain disruptions are expected to have a substantial impact on the critical limb ischemia treatment market share, as dependence on specialized balloons, stents, catheters, atherectomy systems, guidewires, and other vascular intervention devices can create procurement delays and limit treatment options when specific products are unavailable. The market is likely to follow a V-shaped recovery pattern, as critical limb ischemia requires timely limb salvage treatment, and delayed procedures can be rescheduled rapidly once affected devices and supporting supplies become available. The market is expected to grow at a CAGR of 5.95%, but supply chain constraints could approximately lower this by 0.5 percentage points, resulting in short-term growth of around 5.45%. As supply conditions normalize through improved availability of peripheral intervention devices, diversified component sourcing, restored manufacturing capacity, and more reliable medical device distribution, critical limb ischemia treatment market growth is expected to gradually return to 5.95%.
The critical limb ischemia treatment market forecasts strategic investment activity driven by advanced revascularization technologies, drug-coated and bioresorbable vascular therapies, minimally invasive interventions, regenerative medicine, and innovative treatments aimed at improving limb salvage and reducing amputation risk.
Key Investment and Funding Activities in the Critical Limb Ischemia Treatment Market, 2025–2026
Aplagon
USD 5.6 Million
In June 2026, Aplagon received USD 5.6 million in financing from Fåhraeus Startup and Growth and the European Innovation Council Fund, alongside Finnish investors, to expand clinical development.
ProVascTec
USD 2.9 Million
In October 2025, ProVascTec received a USD 2.9 million Enterprise Ireland Disruptive Technologies Innovation Fund grant to advance PulseCLTI, a cell-therapy treatment designed to restore blood flow in patients with critical limb ischemia, through prototype development, preclinical testing, and regulatory preparation.
Aveera Medical
USD 1.03 Million
In August 2025, Aveera Medical received a USD 1.03 million NIH/NHLBI grant to develop its Native Deep Vein Arterialization procedure using the Boomerang System for patients with no-option chronic limb-threatening ischemia, with the goal of reducing major amputations.
Diabetic Foot Ulcer Burden and Ischemic Wound Healing Needs Drive Market Demand
Diabetic foot ulcers associated with peripheral artery disease (PAD) increase the need to restore blood flow and support limb salvage. Treatment pathways include peripheral angioplasty, stent placement, and other endovascular therapy approaches to improve limb perfusion. Greater use of vascular treatment for these complex wounds strengthens demand for critical limb ischemia (CLI) care.
Poor blood flow in ischemic limbs delays tissue repair and increases the clinical need for revascularization. Restoring circulation supports wound closure and tissue recovery in patients with advanced chronic limb-threatening ischemia (CLTI). This need strengthens the use of atherectomy, vascular intervention, and vascular surgery within cardiovascular care.
Contrast-Related Renal Risks and Restenosis Issues Limit Market Expansion
Contrast use during endovascular therapy can increase treatment concerns for patients with impaired kidney function. These risks can restrict the use of contrast-based vascular intervention in some high-risk patients and complicate treatment planning.
Restenosis after peripheral angioplasty or stent placement can reduce the durability of restored blood flow. Recurrent vessel narrowing can require repeat revascularization and additional follow-up, increasing the treatment burden in advanced peripheral artery disease (PAD).
Development of Vascular Imaging Platforms and Specialized Distal Intervention Devices Offer Growth Opportunities
Vascular imaging and planning platforms can combine vessel images, lesion measurements, and clinical information to support treatment planning before complex endovascular therapy. Technology providers can build software that helps clinicians map diseased vessels and select suitable treatment approaches for patients with advanced blood vessel disease.
Specialized pedal and tibial devices can address difficult distal vessel anatomy during lower limb interventions. Manufacturers can design dedicated peripheral vascular devices for vessel access and treatment in complex cases where standard equipment has limited suitability. This creates a focused product opportunity for vascular surgery and limb salvage programs.
Gaps in Wound Vascular Coordination and Concentrated CLTI Services Hinder Market Growth
Fragmented coordination between wound clinics, diabetes care teams, and vascular specialists can delay referral and treatment for patients with chronic limb-threatening ischemia (CLTI). Separate care pathways can slow movement from wound assessment to revascularization and limb salvage treatment.
Specialized CLTI services are concentrated in major vascular centers with advanced teams and facilities. Limited access to these centers can delay vascular intervention for patients in smaller cities and underserved regions. This uneven service distribution can restrict broader access to cardiovascular care.
The devices segment accounted for a share of 54.62% in 2025, supported by the established use of endovascular and revascularization devices for restoring blood flow in patients with severe limb ischemia. Their role in improving vessel patency and supporting limb salvage contributes to strong clinical demand.
The regenerative and cell-based therapies segment is expected to grow at a CAGR of 7.86% during the forecast period, driven by interest in therapies that promote new blood vessel formation and tissue repair in patients with limited revascularization options. Their potential to address poor blood flow at the tissue level supports continued clinical development.
Request Customizationto receive a tailored report.
The hospitals segment accounted for a share of 68.43% in 2025, owing to the need for specialized vascular teams, advanced imaging systems, and surgical facilities for managing severe limb ischemia. Hospitals also provide access to complex revascularization and limb salvage procedures.
The ambulatory surgical centers segment is expected to grow at a CAGR of 6.48% during the forecast period, fueled by the increasing shift toward minimally invasive vascular procedures and shorter recovery times. Their expanding procedural capabilities support treatment of selected peripheral vascular cases in outpatient settings.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Strengthened by Established Limb Salvage Revascularization and Specialized Vascular Care
The North America critical limb ischemia treatment market accounted for the largest regional share of 43.31% in 2025, supported by established limb salvage revascularization and specialized vascular care for patients with advanced peripheral arterial disease.
The U.S. market is supported by endovascular revascularization and limb preservation pathways. Under a CMS policy effective April 2026, endovascular, surgical, or hybrid revascularization is recommended for chronic limb threatening ischemia to minimize tissue loss, heal wounds, relieve pain, and preserve functional limbs, supporting the market adaptability.
The Canada market benefits from established vascular referral pathways for nonhealing wounds, gangrene, and diabetic foot ulcers. The Canadian Society for Vascular Surgery identifies these conditions as urgent indications for vascular assessment, supporting timely treatment of advanced limb ischemia.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Fueled by Adoption of Peripheral Drug Therapy and Focus on Diabetes Management
The Asia Pacific critical limb ischemia treatment market is expected to grow at a CAGR of 7.27% during the forecast period, showcasing the fastest-growing regional market.
The Japan critical limb ischemia treatment market is propelled by below-knee drug-eluting devices and regenerative treatment approaches for severe lower limb ischemia. In 2026, Japan’s clinical trial registry listed the DIAMOND BTK study, evaluating a drug-eluting stent system for below-knee arterial lesions in patients with chronic limb-threatening ischemia.
The China critical limb ischemia treatment market benefits from growing adoption of drug-coated balloon therapy and atherectomy-based lesion treatment. For instance, Beijing health authorities reported the use of rotational atherectomy combined with balloon expansion and stent placement for severe lower limb ischemia.
The India critical limb ischemia treatment market is supported by diabetic foot ischemia management and standardized peripheral artery disease assessment. Government treatment guidelines recommend ABI, Doppler studies, and advanced vascular imaging for patients with diabetic foot ulcers, with urgent specialist assessment for severe ischemia, strengthening structured treatment pathways for chronic limb-threatening ischemia.
Europe: Growth Driven by Modernization of Healthcare Infrastructure
The Europe critical limb ischemia treatment market is expected to grow at a CAGR of 5.41% during the forecast period due to emerging treatment approaches.
The UK market benefits from percutaneous deep venous arterialization for patients with limited treatment options. NICE currently recommends the procedure under special arrangements for clinical governance, consent, audit, and research, creating a defined pathway for this emerging CLTI treatment.
The Germany critical limb ischemia treatment market is expected to benefit from continued modernization of hospital infrastructure and specialized vascular care. Germany’s Hospital Transformation Fund will provide up to USD 58 billion through 2035 for hospital modernization, while USD 4.1 billion is allocated to hospital modernization in 2027, supporting infrastructure upgrades relevant to advanced vascular and limb-salvage procedures.
Latin America Growth Supported by Focus on Specialized Wound Care
The Latin America critical limb ischemia treatment market is expected to grow at a CAGR of 5.83% during the forecast period. Mexico’s National Hospital Infrastructure Plan targets 9,139 additional hospital beds by September 2030 through an investment of approximately USD 10.0 billion, including 50 new hospitals, 47 expansions, and 55 major replacements or upgrades. In Brazil, the Ministry of Health notes that peripheral artery disease in people with diabetes can cause foot ulcers and that diabetes accounts for about 85% of lower limb amputations, highlighting the need for limb preserving treatment.
Middle East & Africa: Market Shaped by Specialist Referral Pathways
The Middle East and Africa critical limb ischemia treatment market is expected to grow at a CAGR of 5.18% during the forecast period, owing to stronger vascular screening and accelerated referral pathways for advanced lower limb ischemia. In the UAE, clinical standards require ankle brachial index and vascular ultrasound assessment for suspected peripheral arterial disease, supporting earlier identification of patients requiring treatment. In South Africa, national clinical guidance classifies rest pain, ulcers, or gangrene as critical limb ischemia and recommends same day specialist referral, supporting faster access to treatment.
The critical limb ischemia treatment market competitive landscape is moderately concentrated, with participation from global cardiovascular and peripheral intervention companies, endovascular device manufacturers, and vascular specialists. Key players such as Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, and Becton, Dickinson and Company are estimated to account for 40–45% of the global critical limb ischemia treatment market share.
Established participants compete primarily through endovascular device performance, lesion crossing and vessel preparation technologies, regulatory approvals, physician training, and hospital distribution networks. Emerging, niche, and regional companies in the critical limb ischemia treatment market ecosystem compete through atherectomy systems, minimally invasive approaches, and cost-efficient products.
April 2026: Reflow Medical reported 12-month results from the DEEPER REVEAL study evaluating the Spur Peripheral Retrievable Stent System in patients with CLTI and below-the-knee arterial disease.
April 2026: REVA Medical announced positive primary-endpoint results from the randomized MOTIV BTK pivotal trial evaluating its MOTIV sirolimus-eluting bioresorbable vascular scaffold in patients with CLTI.
October 2025: Stempeutics and MEDINET Japan signed an option license agreement for Stempeucel, a cell-based therapy being developed for chronic limb-threatening ischemia (CLTI).
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Cervical Cancer Treatment Market Size, Share, Growth, Analysis, 2034
Empty Capsule Market Size, Share, Growth, Analysis, Report, 2034
North America Aesthetic Medicine Market Size, Growth, Report to 2034
Anti-HIV Drugs Market Size, Share, Growth, Analysis, Report, 2034
Pemetrexed Market Size, Share, Growth, Analysis, Report, 2034
Antacids Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com